Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) Short Interest Update

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) was the recipient of a large increase in short interest during the month of February. As of February 27th, there was short interest totaling 6,287,676 shares, an increase of 15.1% from the February 12th total of 5,464,532 shares. Based on an average daily volume of 8,304,137 shares, the days-to-cover ratio is presently 0.8 days. Approximately 6.8% of the shares of the company are short sold. Approximately 6.8% of the shares of the company are short sold. Based on an average daily volume of 8,304,137 shares, the days-to-cover ratio is presently 0.8 days.

Hedge Funds Weigh In On Compass Pathways

Several hedge funds have recently modified their holdings of CMPS. Flax Pond Capital LLC acquired a new stake in Compass Pathways in the 4th quarter worth approximately $364,000. Caitong International Asset Management Co. Ltd acquired a new position in Compass Pathways during the 4th quarter valued at approximately $47,000. Seven Fleet Capital Management LP purchased a new position in shares of Compass Pathways in the fourth quarter worth $276,000. Corient Private Wealth LLC raised its holdings in shares of Compass Pathways by 3.2% in the fourth quarter. Corient Private Wealth LLC now owns 38,438 shares of the company’s stock worth $265,000 after buying an additional 1,200 shares during the last quarter. Finally, XTX Topco Ltd grew its holdings in shares of Compass Pathways by 457.5% during the fourth quarter. XTX Topco Ltd now owns 56,786 shares of the company’s stock valued at $392,000 after buying an additional 46,600 shares during the last quarter. Institutional investors and hedge funds own 46.19% of the company’s stock.

Compass Pathways Stock Down 2.0%

Shares of NASDAQ CMPS traded down $0.13 during trading hours on Tuesday, hitting $6.19. 1,720,703 shares of the stock were exchanged, compared to its average volume of 3,044,629. Compass Pathways has a 12 month low of $2.25 and a 12 month high of $8.90. The firm has a fifty day moving average price of $6.99 and a 200-day moving average price of $6.26. The company has a quick ratio of 1.23, a current ratio of 1.23 and a debt-to-equity ratio of 0.55. The company has a market cap of $593.88 million, a PE ratio of -2.27 and a beta of 1.90.

Wall Street Analyst Weigh In

Several equities research analysts have commented on the stock. Canaccord Genuity Group upped their price objective on shares of Compass Pathways from $15.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, February 18th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Pathways in a research report on Wednesday, January 21st. HC Wainwright boosted their price objective on Compass Pathways from $40.00 to $70.00 and gave the stock a “buy” rating in a report on Monday, March 2nd. Lifesci Capital upgraded shares of Compass Pathways to a “strong-buy” rating in a research report on Thursday, February 12th. Finally, Royal Bank Of Canada raised their price objective on Compass Pathways from $21.00 to $22.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, Compass Pathways has a consensus rating of “Moderate Buy” and an average target price of $22.13.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.